In this episode, Jacqueline S. Garcia, MD, discusses novel agents and strategies in clinical trial development for treating patients with myelofibrosis, including:

• Navitoclax (BCL-XL/BCL-2 inhibitor)
• Pelabresib (BET inhibitor)
• Imetelstat (telomerase inhibitor)
• Luspatercept (erythroid maturation agent)
• Additional strategies

Presenter:  

Jacqueline S. Garcia, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Link to the full program here. https://bit.ly/47z8WCV